Refine your search

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

This is a study of the drug DFMO (difluoromethylornithine) for neuroblastoma that has returned or not responded to treatment. DFMO is an oral drug that inhibits a certain enzyme (protein) in blood which is associated with a bad outcome in neuroblastoma cases. Cancer cells have pathways that drive the cancer to grow and DFMO targets the specific pathway of this enzyme to turn these cells off.
Suzanne Treadway at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT04301843
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Up to 31 years old with history of relapsed/refractory neuroblastoma.
Completed upfront therapy with at least 4 cycles of aggressive multi-drug chemotherapy
Exclusion Criteria:
Received a dose of DFMO in combination with etoposide
Currently receiving another investigational drug
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA